News
Eli Lilly is tagging along on actress Kym Whitley’s blockbuster summer in a fresh Zepbound partnership with the “Happy ...
Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...
David Mooney, who most recently served as Chief of Cyber Protective Services at the Cybersecurity and Infrastructure Security ...
6hon MSN
Penn CRISPR science is the foundation for a gene-editing heart disease treatment under Eli Lilly
What if a heart attack and lifetime of statin drugs could be avoided with a one-time, two-hour infusion? Kiran Musunuru, a University of Pennsylvania cardiologist and leading gene-editing researcher, ...
The Investment Committee debate the latest Calls of the Day. Donald Trump suffers major legal loss in "deep state" war Watch ...
Finally, don't discount legal challenges to the president's tariffs. An argument could be made that pharmaceutical products ...
Explore more
After a nine-month investigation into direct-to-consumer telehealth platforms launched by Eli Lilly and Pfizer, a group of ...
Eli Lilly and Company (NYSE:LLY) is one of the stocks in Jim Cramer’s spotlight. Answering a caller’s query about the company ...
Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.
The opportunity to “ talk to a doctor now ” increases access to care, the drug companies say. But the legislators, and some ...
Shares of Eli Lilly & Co. LLY rallied 1.34% to $771.71 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.01% to 6,296.79 and ...
Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results